NASDAQ:CRVO CervoMed Q4 2024 Earnings Report $8.47 +0.05 (+0.59%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.54 +0.06 (+0.77%) As of 05/23/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CervoMed EPS ResultsActual EPS-$0.80Consensus EPS -$0.67Beat/MissMissed by -$0.13One Year Ago EPSN/ACervoMed Revenue ResultsActual Revenue$2.16 millionExpected Revenue$1.51 millionBeat/MissBeat by +$646.00 thousandYoY Revenue GrowthN/ACervoMed Announcement DetailsQuarterQ4 2024Date3/17/2025TimeBefore Market OpensConference Call DateTuesday, March 18, 2025Conference Call Time4:00PM ETUpcoming EarningsCervoMed's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) CervoMed Earnings HeadlinesCervoMed Inc. (NASDAQ:CRVO) Receives $27.63 Average PT from AnalystsMay 24 at 1:37 AM | americanbankingnews.comCervoMed Stock Short Interest Report | NASDAQ:CRVO | BenzingaMay 18, 2025 | benzinga.comThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah Mountains in Utah. Bezos, Buffett, and Gates are getting involved. But few Americans know why this remote patch of land is suddenly worth billions. One of our own insiders even filed a FOIA request in Washington to get to get the truth.May 24, 2025 | Stansberry Research (Ad)CervoMed Q2 EPS Lifted by Brookline Capital ManagementMay 17, 2025 | americanbankingnews.comRoth Capital Brokers Lower Earnings Estimates for CervoMedMay 16, 2025 | americanbankingnews.comCervoMed First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | uk.finance.yahoo.comSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
